Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs MK-677 (Ibutamoren)
An educational, source-based comparison of CJC-1295 and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| CJC-1295 | Sustained pharmacological GH activity in healthy adults via DAC technology | Journal of Clinical Endocrinology & Metabolism | 2006 | Established prolonged GH/IGF-1 elevation from single subcutaneous doses. |
| CJC-1295 | GHRH analogs and the GH-IGF-1 axis | Endocrine Reviews | 2011 | Mechanistic review of GHRH-analog pharmacology. |
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
Side-effect & safety grid
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
CJC-1295 vs MK-677 (Ibutamoren) — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: Growth hormone vs Growth hormone · Oral.